PEDIATRIC COVID VACCINE STUDY

The HUMMINGBIRD study is testing an investigational vaccine that is designed to prevent coronavirus disease 2019 (COVID-19).

The study vaccine is a protein-based (or traditional) vaccine and is not an mRNA vaccine.

NVX-CoV2373 has been authorized in various countries for adolescents and adults 12 years of age and older.

Now, researchers are evaluating it for children ages 6 months to 2 years.

To be eligible for this study, your child must:
• Be 6 months to 2 years of age
• Not have received a previous vaccine to protect against COVID-19

• Not have received any medications to prevent or treat COVID-19

This is not a complete list of eligibility criteria. The study doctor
will review the full entry criteria for this study with you.

Call (972) 746-2222 Now to Find Out if Your Child Qualifies for this Study.

Leave a message if after or before business hours, and a screener will call you on the next business day.